Evidence map›Paper›PMID 31669212›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease.

Fan Yu, Min Zheng, Alice Yang Zhang, Zongchao Han

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 109 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Fan YuJiangsu Provincial Key Laboratory of Coastal Wetland Bioresources, School of Pharmacy, Yancheng Teachers University, Yancheng City, Jiangsu Province, PR China; Department of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Min ZhengDepartment of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Alice Yang ZhangDepartment of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Zongchao HanDepartment of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: zongchao@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Targeting Retinitis Pigmentosa Using Nanoparticle-Mediated Delivery of Genomic DNAR01EY026564 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAN, ZONGCHAO · 2016 to 2020
$1.9M
NEI NIH HHS R01 EY026564
6 · The paper itself

Abstract

Dry eye (DE) disease is an uprising health epidemic that directly affects the surface of the eye. We developed a water soluble cerium oxide loaded glycol chitosan nanoparticle as a new type of eye drop, namely GCCNP (glycol chitosan cerium oxide nanoparticles). GCCNP is capable of scavenging cellular reactive oxygen species (ROS) for the treatment of DE disease. The antioxidative effects of GCCNP were assessed in mice primary corneal and conjunctival cells in vitro and in a DE murine model in vivo. GCCNP's effect on the DE models was assessed via histological evaluations, migration assays, cell viability assays, cellular uptake analyses, intracellular ROS scavenging assays, wound healing assays, mitochondrial membrane potential readings, corneal fluorescein staining, tear volume concentrations, tear film break up time analyses, and lastly, analytical/spectroscopic analyses of GCCNP eye drop formulations. Spectroscopic analysis showed that cerium oxide was entrapped into the glycol chitosan (GC). The solubility of cerium in GC (GCCNP) increased to 709.854±24.3μg/ml compared to its original solubility in cerium oxide, which was measured as 0.020±0.002μg/ml. GCCNP had no cytotoxic effect and showed improvements on dry eye disease models by stabilizing the tear film, scavenging ROS, up-regulating SOD, promoting and maintaining corneal and conjunctival cell growth and integrity. We provided convincing evidence that GCCNP is an effective treatment for DE and may represent a potential new class of drug for DE disease.

Indexed as

NanoparticlesAnimalsAntioxidantsCeriumChitosanConjunctivaCorneaDisease Models, AnimalDry Eye SyndromesFemaleMiceMice, Inbred C57BLReactive Oxygen SpeciesSolubilitySuperoxide DismutaseTearsAntioxidantsceric oxideCeriumChitosanglycol-chitosanReactive Oxygen SpeciesSuperoxide DismutaseAntioxidant nanoparticlesDry eye diseaseReactive oxygen species (ROS)

Identifiers

PMID31669212
PMCPMC6925533
OpenAlexW2981946645

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.